BLFS - バイオライフ・ソリュ―ションズ (BioLife Solutions Inc.) バイオライフ・ソリュ―ションズ

 BLFSのチャート


 BLFSの企業情報

symbol BLFS
会社名 Biolife Solutions Inc (バイオライフ・ソリュ―ションズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 医薬品   医療関連(Health Care)
概要 事業概要 BioLife Solutions Inc. (BioLife) is engaged in the developing manufacturing and marketing a portfolio of biopreservation tools and services for cells tissues and organs including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Company's product offerings include hypothermic storage and cryopreservation freeze media products for cells tissues and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications and contract aseptic manufacturing formulation fill and finish services of liquid media products. Its products include HypoThermosol FRS CryoStor BloodStor Cell Thawing Media PrepaStor and biologistex cold-chain management service.   バイオライフ・ソリュ―ションズは、米国のバイオプリザベ―ション製品メ―カ―。細胞や組織用の低体温貯蔵と凍結保存ソリュ―ションの特許を所有し、製品の開発、製造、販売を手掛ける。バイオバンク、創薬、再生医療、毒性試験、診断市場を対象に主要製品HypoThermosol、CryoStor、BloodStor、SAVSUなどを提供する。   BioLife Solutions, Inc. engages in the development, manufacture and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.
本社所在地 3303 Monte Villa Parkway Suite 310 Bothell WA 98021 USA
代表者氏名 Raymond Wayne Cohen レイモンドウェインコーエン
代表者役職名 Independent Chairman of the Board
電話番号 +1 425-401-1400
設立年月日 1987年
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 40人
url www.biolifesolutions.com
nasdaq_url https://www.nasdaq.com/symbol/blfs
adr_tso
EBITDA EBITDA(百万ドル) 1.49751
終値(lastsale) 12.95
時価総額(marketcap) 231679151.9
時価総額 時価総額(百万ドル) 236.50950
売上高 売上高(百万ドル) 15.09058
企業価値(EV) 企業価値(EV)(百万ドル) 236.45623
当期純利益 当期純利益(百万ドル) -0.14596
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 BioLife Solutions Inc revenues increased 83% to $9M. Net income applicable to common stockholders totaled $943K vs. loss of $1.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest expense decrease of 99% to $2K (expense) Loss from equity-method investment in SA decrease of 35% to $321K (expense).

 BLFSのテクニカル分析


 BLFSのニュース

   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat  2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
   BioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock  2020/07/07 16:45:00 PR Newswire
BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of…
   BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock  2020/07/02 11:40:00 Benzinga Feeds
BOTHELL, Wash. , July 2, 2020 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75 million . The offering is expected to close on July 7, 2020, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 776,250 shares of common stock from BioLife at the public offering price, less underwriting discounts and commissions. BioLife anticipates using net proceeds from the offering for general corporate purposes, which includes, without limitation, potentially investing in or acquiring companies that are synergistic with or complementary to our technologies, and working capital.
   BioLife Solutions Announces Proposed Public Offering of Common Stock  2020/07/01 20:01:00 PR Newswire
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common…
   The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results  2020/07/23 12:25:53 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) BioLife Solutions Inc (NASDAQ: BLFS ) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Catalent Inc (NYSE: CTLT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunic Inc (NASDAQ: IMUX ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) ( reported forecast-beating second-quarter results) Medpace Holdings Inc (NASDAQ: MEDP ) Novo Nordisk A/S (NYSE: NVO ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Otonomy Inc (NASDAQ: OTIC ) Penumbra Inc (NYSE: PEN ) Qiagen NV (NYSE: QGEN ) Quest Diagnostics Inc (NYSE: DGX ) ResMed Inc. (NYSE: RMD ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 22) Akouos Inc (NASDAQ: AKUS ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Forma Therapeutics Holdings Inc (NASDAQ: FMTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Nkarta Inc (NASDAQ: NKTX ) RENALYTIX AI ADR (NASDAQ: RNLX ) (went public Friday) Tricida Inc (NASDAQ: TCDA ) Stocks In Focus Midatech Terminates Sale Process, Strategic Review to Continue Midatech Pharma PLC-ADR (NASDAQ: MTP ), a drug delivery technology company, said it has terminated the formal sale process initiated in late April after it failed to receive any proposals from third parties.
   The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat  2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
   BioLife Solutions Announces Closing of $86 Million Public Offering of Common Stock  2020/07/07 16:45:00 PR Newswire
BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of…
   BioLife Solutions Announces Pricing of $75 Million Public Offering of Common Stock  2020/07/02 11:40:00 Benzinga Feeds
BOTHELL, Wash. , July 2, 2020 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting discounts and commissions. The gross proceeds from the offering to BioLife, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75 million . The offering is expected to close on July 7, 2020, subject to the satisfaction of customary closing conditions. In addition, the underwriters have a 30-day option to purchase up to an additional 776,250 shares of common stock from BioLife at the public offering price, less underwriting discounts and commissions. BioLife anticipates using net proceeds from the offering for general corporate purposes, which includes, without limitation, potentially investing in or acquiring companies that are synergistic with or complementary to our technologies, and working capital.
   BioLife Solutions Announces Proposed Public Offering of Common Stock  2020/07/01 20:01:00 PR Newswire
BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced it intends to offer shares of its common…
   BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales  2020/05/18 20:15:00 PR Newswire
BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the…
   BioLife Solutions Announces First Quarter 2020 Financial Results  2020/05/14 20:05:00 PR Newswire
BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced financial results for the three months ended…
   Why Earnings Season Could Be Great for BioLife Solutions (BLFS)  2020/05/13 14:20:00 Zacks Investment Research
BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   BioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020  2020/05/11 12:00:00 PR Newswire
BOTHELL, Wash., May 11, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that the Company's first quarter 2020…
   BioLife Solutions Announces Preliminary First Quarter 2020 Revenue  2020/05/01 12:00:00 PR Newswire
BOTHELL, Wash., May 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced preliminary revenue for the first quarter of…

 関連キーワード  (医薬品 米国株 バイオライフ・ソリュ―ションズ BLFS BioLife Solutions Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)